

The Forum HIV Prevention Trial Design Public Meeting Series

Webinar 1: High-level review of regulatory frameworks and lessons learned to date

October 14, 11 am-1 pm EST

Webinar

Overview

This first webinar will review the regulatory framework for clinical trial innovation relevant for PrEP. Regulatory experts from the EU and US will provide a high-level overview, and we will get a glimpse of how a normative body, the WHO interacts with regulatory agencies. Then, we will review how far we have come in PrEP research in the context of the regulatory framework and discuss why we need innovation in trial design for this global health need. This will set the stage for the 2nd webinar (Date to be confirmed) in which we will feature additional high-level regulatory overviews, and discuss the potential path forward. The goal of the two information webinars is to bring the audience up to speed and facilitate their engagement in strategic discussions on forging a feasible path forward. Both webinars will be archived for future access.

AGENDA

<p>11:00 AM Welcome & Housekeeping</p>		
	<p>Introductory remarks</p> <p>Opening remarks</p>	<p><i>Tamar Tchelidze, MD, MPH, Sr. Policy Fellow. Forum for Collaborative Research, UC Berkeley</i></p> <p><i>Veronica Miller, PhD, Executive Director, Forum for Collaborative Research, UC Berkeley</i></p> <p><i>Ken Mayer, MD, Medical Research Director. The Fenway Institute/Harvard Medical School</i></p>
<p>11:10 AM Session I: High-level Overview of Regulatory Frameworks & Innovations</p>		
	<p>Regulatory Frameworks - EU Perspective</p> <p>WHO and EMA: Dapivirine Ring Case Study</p>	<p>Moderator: Veronica Miller</p> <p><i>Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicines Agency (EMA)</i></p> <p><i>Rachel Baggaley, MD, Unit Head, World Health Organisation (WHO)</i></p> <p><i>Veronica Miller, PhD, Forum for Collaborative Research; Jeffrey Murray, MD, MPH, Deputy director of Division of Antiviral Products, FDA; Community Representatives: Grace Kumwenda, BA, Pakachere Institute of Health & Development Communication (Africa); Gus Cairns, MA the PrEP in Europe Initiative/EATG, (EU); Mitchell Warren, BA, AVAC (US)</i></p>
11:30 AM	Moderated discussion with panelists	
<p>12:00 PM Session II: What have we learned thus far</p>		
	<p>Lessons from PrEP trials to date</p> <p>When & why will these approaches no longer "work"?</p> <p>Moderated Interactive Panel Discussion: Why do we need a new path forward? Continuing unmet medical need</p> <p>Q & A</p>	<p>Moderator: Veronica Miller</p> <p><i>Deborah Donnell, PhD, Principal Staff Scientist, the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center/HPTN</i></p> <p><i>Charu Mullick, MD, Medical Officer, U.S. Food and Drug Administration (FDA)</i></p> <p><i>Sinead Delany-Moretlwe, PhD, Associate Professor and Director of Research, University of the Witwatersrand; Community representatives: Ntando Yola, BA, Desmond Tutu Health Foundation (Africa); Stacey Hannah, MHS, AVAC (US)</i></p>
12:50 PM	Summary and introduction to next webinar	<i>Veronica Miller, PhD, Forum for Collaborative Research/ UC Berkeley</i>
1:00 PM	ADJOURN	